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Abstract 
 
The therapeutic drug monitoring (TDM) of pharmaceutical drugs with narrow therapeutic ranges 
is of great importance in the clinical setting. It provides useful information towards the enhancement of 
drug therapies, aiding in dosage control and toxicity risk management. Amikacin is an aminoglycoside 
antibiotic commonly used in neonatal therapies that is indicated for TDM due to the toxicity risks inherent 
in its use. Current techniques for TDM such as high performance liquid chromatography (HPLC) and gas 
chromatography-mass spectrometry (GC-MS) are costly, time consuming, and cannot be performed at the 
site of action. Over the last decades, surface plasmon resonance (SPR) biosensors have become 
increasingly popular in clinical diagnostics due to their ability to detect biomolecular interactions in real-
time. 
We present an SPR-based competitive immunoassay for the detection of the antibiotic amikacin, 
suitable for TDM in both adults and neonates. We have obtained high specificity and sensitivity levels 
with an IC50 value of 1.3 ng/mL and a limit of detection of 0.1 ng/mL, which comfortably comply with 
the drug’s therapeutic range. Simple dilution of serum can therefore be sufficient to analyze low-volume 
real samples from neonates, increasing the potential of the methodology for TDM. Compared to current 
TDM conventional methods, this SPR-based immunoassay can provide advantages such as simplicity, 
potential portability, and label-free measurements with the possibility of high throughput. This work is 
the foundation towards the development of an integrated, simple use, highly sensitive, fast, and point-of-
care sensing platform for the opportune TDM of antibiotics and other drugs in a clinical setting. 
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1. Introduction 
 
In the last decade research related to immunosensors has been focused towards the development 
of point-of-care devices that can allow management of a particular issue whether it is food safety, 
security, environmental, or medical related [1, 2]. Therapeutic drug monitoring (TDM) is a branch of 
clinical chemistry and pharmacology that specializes in the measurement of therapeutic drug 
concentrations in blood or other body fluids. TDM is indicated for drugs that have narrow therapeutic 
ranges, i.e. drugs that present a high risk of toxicity when overdosed or ineffectiveness when underdosed 
[3]. Moreover, neonate (newborn) patients have unique drug dispositions that indicate the need of TDM 
in order to ensure a safe drug therapy [4]. This monitoring aims to enhance drug efficacy through toxicity 
risk management, dosage control, and assistance in clinical diagnosis [5, 6].  
Antibiotics are drugs that are suitable for TDM and they are the most widely used drugs in 
neonatal therapy due to newborns’ high susceptibility to infections [7]. Amikacin (AK) is an 
aminoglycoside antibiotic commonly used in neonatal therapies [8, 9], and is indicated for TDM due to 
the toxicity risks inherent to its use as well as its narrow therapeutic range (1-30 µg/mL) [10, 11]. TDM of 
Amikacin and other pharmaceutical drugs is mostly performed in blood serum or plasma [6, 12] and 
given the low blood volume in neonates of approximately 80 mL/kg, small sample sizes are most 
desirable in order to avoid detrimental impact to the patient due to blood loss [4]. Current conventional 
methods for TDM are high performance liquid chromatography (HPLC) [13, 14], gas chromatography-
mass spectrometry (GC-MS) [15, 16], and other commercial immunoassays [17, 18] (if available for the 
desired analyte), which are costly and time consuming. Additionally, these methods are complex and 
cannot be performed at the site of action [6].  
Surface plasmon resonance (SPR) is a widely known optical technique thoroughly studied in the 
last few decades, which uses evanescent waves to investigate surface phenomena and generate a signal 
related to a change in refractive index at an interface. It has become popular in a variety of fields 
including environmental protection, fundamental biological studies, food safety and clinical diagnosis 
applications [19]. Advantages of SPR biosensing include real-time and label-free monitoring, simplicity, 
high levels of sensitivity and fast-response measurements, making it a potential alternative to current 
clinical and laboratory measurement techniques such as enzyme immunoassays (ELISA, EMIT) and 
chromatographic techniques (LC-MS, HPLC) [19, 20]. While SPR biosensing has been used for the 
detection of antibiotics in milk samples for food safety applications [21, 22], their application for TDM 
purposes, especially in neonates, has not been approached. The antibiotic kanamycin has been monitored 
using a fluorometric technique based on plasmon resonance light-scattering (PRLS) of gold nanoparticles 
(AuNPs) [23], albeit in urine samples for monitoring of nephrotoxicity and ototoxicity.  
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In this work we present a SPR-based competitive immunoassay for the detection of AK, suitable 
for TDM in both adults and neonates. We have obtained high specificity levels and a high sensitivity 
which complies with the drug’s therapeutic range, demonstrating the effectiveness of this approach to 
further point-of-care on-site TDM monitoring. 
 
2. Materials and Methods 
2.1 Chemicals and Reagents 
 
Reagents for the self-assembled monolayer (SAM) formation (16-mercaptohexadecanoic acid 
(MHDA) and 11-mercaptoundecanol (MUOH)), common reagents (N-hydroxysuccinimide (NHS), 1-
ethyl-3(3-dimethylamino-propyl) carbodiimide hydrochloride (EDC), ethanolamine), inorganic salts for 
buffer preparation (phosphate buffer saline (PBS), 2-(N-morpholino)ethanesulfonic acid (MES), Tween 
20), bovine serum albumin (BSA) and AK were purchased from Sigma Aldrich. 
Polyclonal IgG anti-AK antibody was purchased from Abcam (England) and AK-BSA conjugate 
was synthesized as described in Section 2.4.  
 
2.2 Instrumentation 
 
SPR measurements were performed using a homemade SPR biosensor based on the Kretschmann 
configuration under a prism-coupling scheme.  A polarized 3 mW laser beam with an operational 
wavelength of 670 nm is directed at a fixed angle towards the gold-coated sensing surface. The sensing 
chips are 10 x 10 x 0.3 mm glass coated with 2 nm of chromium and 45 nm of gold, from Ssens 
(Netherlands). SPR measurements are performed at a fixed angle of incidence. The optimum 
measurement angle is selected during calibration to ensure maximum sensitivity to changes in the 
refractive index, which in turn are caused by mass variations at the sensing surface. These variations are 
detected as changes in the reflected light intensity at a photodiode, and are subsequently amplified and 
converted to a digital signal, which we refer to as SPR signal (intensity variation of the reflected light at a 
fixed angle). 
Sample sizes of 250 µL are injected by a diaphragm pump to the flow delivery system, which 
incorporates a flow cell with two independent channels. The system incorporates all the optics, electronics 
and fluidic components necessary to function autonomously.  
 
2.3 Synthesis of the AK-BSA conjugate 
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AK-BSA conjugate was prepared based on the conjugation of the amino groups of AK to the 
carboxylic groups present in BSA. Briefly, a solution of AK (11.11 mg/ml in MES buffer pH 5.0) and the 
carrier protein BSA (10 mg/ml in MilliQ water) was incubated for 3 hours with 10 mg of EDC as a linker. 
Next, purification of the conjugate was achieved by using PBS 10 mM (pH 7.4) as a purifying buffer and 
a 30 kDa centrifugal filter. The solution was mixed with 250 µL of purifying buffer in the filter and was 
centrifuged at 12000 RPM during 120 s, after which the residues from the collection tube were discarded. 
This process was repeated three times, yielding the final conjugate solution. Conjugate concentration was 
determined by UV resulting in 14.3 mg/ml. 
 
2.4 Immobilization Procedure 
 
Gold chips were prepared for immobilization by a wash with ethanol, followed by 20 minutes of 
surface cleansing with UV-ozone (Bioforce Nanosciences, Inc, model UV-TC.220) to eliminate organic 
contamination. A second rinse with ethanol was performed and finally the chips were dried with N2. 
A covalent strategy was used for biofunctionalization of the surface. After chip cleaning, the 
formation of an alkanethiol self-assembled monolayer (SAM) was carried out ex-situ by coating the gold 
chip overnight with a mixed solution of MHDA:MUOH in ethanol, with a molar ratio of 1:1 and at a total 
concentration of 250 µM. The chip was rinsed with ethanol and dried with N2, and mounted in the SPR 
platform. Next, an AK-BSA conjugate was covalently coupled to the carboxylic groups of the SAM 
through activation of the acid groups with a solution of 0.2 M EDC and 0.05M NHS in MES buffer (pH 
5.0). Subsequently, after the concentration of AK-BSA conjugate in PBS buffer was injected, a 1 M 
ethanolamine solution (pH 8.5) was used for the deactivation of unreacted carboxylic groups. This 
procedure was done at a flow-rate of 14 µL/min. 
 
2.5 SPR immunoassay format 
 
 An indirect competitive immunoassay format was used for the detection of AK levels given the 
low molecular weight of the molecule (585.60 Da). Therefore, the AK-BSA conjugate was immobilized 
and used as the sensing bioactive surface. After assay optimization, samples consisting of mixtures (1:1 
v/v) of different analyte concentrations (ranging from 1 pg/mL to 5 µg/mL in PBS or PBST (0.05% 
Tween 20)) and a fixed antibody concentration were flowed over the sensing layer at a speed of 22 
µL/min. Samples were incubated for 10 min at room temperature before injection and monitoring was 
performed in real time. Since antibody binding to the immobilized conjugate is inhibited by the presence 
of analyte, lower analyte concentrations resulted in high SPR signals and vice versa. Standard calibration 
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curves were constructed with at least 7 points (7 different AK concentrations) with three replicate 
measurements each. Reutilization of the sensor surface was achieved using a solution of NaOH 45 mM as 
a regeneration solution, during 120 s at a speed of 22 µL/min after each sample injection.  
 
2.6 Data analysis 
 
Standard calibration curves were obtained by plotting the average SPR signal and standard 
deviation of three samples for each AK concentration, versus the logarithm of the AK concentration of 
the sample. These experimental points were fitted to the four-parameter logistic equation: 
 
      	/	1  /	 
 
where y is the SPR signal (variation of reflectance at a fixed angle, % Reflectance), A is the maximum 
signal (zero concentration of analyte), D is the asymptotic minimum (background signal), B is the slope of 
the sigmoidal curve at the inflection point, and C is the concentration which gives 50% of the maximum 
signal, IC50). 
 
3. Results and Discussion 
 
Molecular weight of the analyte is a key factor when selecting the immunoassay configuration in 
SPR biosensing. A direct assay configuration (which uses an antibody coated surface) may be the best 
option in order to simplify conditions, even more with views of developing point-of-care devices, but it 
becomes an unfeasible approach due to the low molecular weight of AK (585.60 Da), which inevitably 
would lead to low detectability. Therefore, we proceeded to the optimization of an indirect competitive 
inhibition assay (Fig. 1), in which samples consisting of a fixed concentration of antibodies incubated 
with different concentrations of the analyte are then flowed over an antigen-coated surface. Compared 
with direct assays, indirect approach avoids some drawbacks related to the immobilization of antibodies 
to the solid surface and their potential loss of affinity, either due to their attachment which can affect the 
native structure, or simply during assay development and optimization. This process usually requires 
working under conditions that allow regeneration of the bioactive surface (i.e. basic or acid conditions 
which disrupt the interactions between the antibody and the target molecule, therefore releasing it and 
leaving the receptor ready for the next sample). Subjecting the antibody coated surface to these conditions 
usually lead to an irreversible alteration of antibody structure, and therefore to its binding ability. 
Moreover, the direct approach has to deal with the proper orientation of the antibodies on the surface, 
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which can also affect the overall assay performance. On the other hand, in an indirect assay the 
immobilization of the target, either directly or through a carrier molecule (typically a protein) which 
previously has been decorated with the analyte, provides a higher degree of robustness and reusability 
even under mild or harsh regeneration conditions. 
 
In the indirect immunoassay, parameters such as antigen conjugate concentration, antibody 
concentration and interaction buffer become crucial to obtain the best features in terms of sensitivity, 
reproducibility and stability. These factors together with the regeneration solution were optimized to 
achieve the best sensor performance. 
AK-BSA conjugate concentrations ranging from 5 to 30 µg/mL of AK-BSA were tested over 
gold substrates coated with a mixed SAM (MHDA:MUOH 1:1). As can be seen in Table 1 a gradually 
increasing amount of conjugate was bound to the surface as the added antigen concentration is also 
higher, until approaching saturation of the surface at 30 µg/mL of AK-BSA. 
 
The concentration of fixed antibody to be used in the inhibition immunoassay influences 
immunoassay characteristics such as the limit of detection (LOD), sensitivity, and dynamic range. 
Additionally, in order to favor competition, a low concentration of free antibody will usually give better 
results. Therefore, there is a trade-off between using low concentrations for a better assay sensitivity, and 
using a concentration high enough (but well below saturation level of the antigens) to obtain discernible 
signals for a wider range of analyte concentrations.  
Several antibody concentrations (up to 6 µg/mL) were tested and the signal obtained did not reach 
saturation in any case. The average signal response when injecting 6 µg/mL of anti-AK antibody over 
chips immobilized with 5, 15 and 30 µg/ml of AK-BSA was of 0.30, 0.53, and 0.78 respectively. As 
could be expected, results showed an overall higher response to the same antibody concentration for 
surfaces in which higher immobilization signals were obtained. Finally an AK-BSA concentration of 30 
µg/mL and an antibody concentration of 6 µg/mL were deemed optimal, guaranteeing a sufficient 
maximum SPR signal in absence of analyte while assuring a wide dynamic range for clear differentiation 
between different analyte concentrations.  
In order to assess the stability of the assay and also to test the reusability and robustness of the 
bioactive surface, we studied several regeneration conditions in order to remove the bound antibody. The 
performance of several acid and basic solutions (i.e. HCl, glycine and NaOH at different concentrations) 
was compared. An effective regeneration is crucial to ensure the reusability of the sensing surface and the 
reproducibility of the measurements. Incomplete removal of antibody will produce disperse 
measurements between replicates and an excessively harsh conditions might compromise the stability of 
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the sensing surface reducing its life span. Regeneration with NaOH 45 mM solution injected for 120 s 
was selected as optimum conditions to achieve complete removal of the bound antibody. These conditions 
ensured the reusability of the surface over a span of 3 days and at least 40 measurement cycles, observing 
then a decrease in the SPR signal of 11% (taking as reference the zero analyte concentration). Stability in 
the day-to-day measurements was evidenced by consistence in the SPR signals, confirming the reliability 
and robustness of the immobilized chips. 
With these initial conditions, calibration curves were performed, both in PBS and PBST (PBS 
containing 0.05% Tween 20) Figure 2 shows sensograms indicating the SPR response to the binding of 
different concentrations of AK, followed by their respective regeneration cycles. As expected, SPR 
signals decrease in response to increasing AK concentrations. 
Significant better performance was obtained using PBST instead of PBS. When using PBS as 
running buffer, lower reproducibility was observed (relatively high standard deviation between 
measurements). On the other hand, the use of PBST resulted in a lower dispersion between replicates and, 
most importantly, in a much higher sensitivity (see Figure 3).  
 
Table 2 summarizes immunoassay features for both buffers and as can be seen a LOD one order 
of magnitude better was reached using PBST instead of PBS, with a slope of the linear area close to 1, 
which may result in a more precise and accurate calibration curve. 
 
Specificity of the sensing surface was evaluated with anti-vancomycin antibody (6 µg/mL) 
obtaining negligible SPR signals (data not shown). Vancomycin (Van) is an antibiotic also used in 
newborn therapies for the treatment of infections caused by Gram-positive bacteria, and can usually be 
coadministered with AK. Thus, the specificity of the current assay was also tested to assess any potential 
cross-reactivity with Van, by performing the inhibition assay with a fixed concentration of anti-AK 
antibody (6 µg/ml) and varying concentrations of vancomycin. As can be seen in Figure 3 no inhibition is 
observed even at high concentrations of vancomycin (9-18% of the maximum signal), which confirms the 
low specificity of the assay towards Van and its suitability for the detection of AK. 
According to the obtained assay features, this SPR-based approach can be very useful for the 
determination of AK since the sensitivity levels obtained are far below the drug’s therapeutic range (1-30 
µg/mL) and comparable or higher than current TDM methods [24–26]. This high sensitivity entails 
advantages for the detection of AK in real human samples by allowing sample dilution of approximately 
5000 times, resulting in sample sizes of few nanoliters. Non-specific binding of matrix components 
present in serum can sometimes produce analytical interference (positive signal) which masks the specific 
signal leading to wrong results. This extremely high dilution fold, (which represents less than 0.02% of 
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sample) becomes convenient in order to minimize the potential negative effects of the complex matrix on 
the sensing surface. Moreover, in intended uses where the clinical samples come from blood drawn from 
infants, the low detectability of the assay overcomes the problems associated with dilution of the sample, 
which sometimes, in assays that show moderate to fair sensitivities, implies to fall below the 
quantification or even the detection limit.  
 
4. Conclusions 
 
A highly sensitive, label-free SPR immunosensor for the therapeutic monitoring of AK has been 
developed. The sensor uses a sample size of 250 µL, but according to the high sensitivity obtained, which 
allows high sample dilution to enter in the working range, very low patient’s sample volume of few 
nanoliters will be presumably required, making the sensor favorable for TDM in neonates while 
maintaining quantification capability. The sensor is based on an indirect competitive immunoassay with 
AK immobilized on the gold surface. The immobilization process and other immunoassay parameters 
were individually optimized for the best performance. We have obtained a very good sensitivity with an 
IC50 value of 1.3 ng/mL. A low LOD of 0.1 ng/mL was achieved, which comfortably complies with the 
drug’s therapeutic range and is adequate for the assay’s application in TDM. Reproducibility in the 
measurements has been also achieved, as well as reusability of the surface for at least 40 measurements 
over a span of 3 days, confirming the robustness of the method. Finally, non-specificity of the assay 
towards Van (a drug often coadministered with AK) was also demonstrated. 
This SPR immunoassay method provides advantages over current TDM conventional methods 
(such as enzyme immunoassays and chromatographic techniques) allowing the fast, label-free and real-
time determination of AK concentrations, while achieving comparable or even lower detection limits. To 
our knowledge this could be the first application of SPR in the therapeutic monitoring of antibiotics. This 
assay demonstrates the potential of SPR as a method for point-of-care TDM of antibiotics (and other 
drugs) in a clinical setting. Future work will involve the evaluation of the technique using real serum 
samples, as well as the detection of other drugs indicated for TDM.  
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Figure Legends 
Fig. 1 Indirect competitive assay. (a) formation of the alkanethiol mixed SAM (b) immobilization of the 
AK-BSA conjugate (c) Samples consisting of a mixture of a fixed antibody concentration and varying 
analyte concentrations are incubated for 10 minutes and flowed over the sensing surface. Reutilization of 
the surface is achieved by means of a regeneration solution 
 
Fig. 2 Sensograms showing the interaction of free anti-AK fraction at different AK concentrations (1) and 
the subsequent regeneration step  with NaOH 45 mM (2) after signal stabilization 
 
Fig. 3 Standard calibration curve for AK in PBS (black) and PBST 0.05% Tween (blue). Each point 
corresponds to the mean value and standard deviation of triplicate measurements. In red, specificity study, 
performed with vancomycin (Van) as analyte instead of AK, using anti-AK antibody under optimized 
assay conditions 
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Table 1: Immobilization of AK-BSA 
[AK-BSA], 
(µg/mL) Immobilization signal, (a.u) 
5 0.33±0.03a 
10 0.85±0.03 
15 0.97±0.07 
30 1.11±0.05 
a: mean signal ± standard deviation of at least 3 replicates 
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Table 2. Amikacin immunoassay features 
 LOD (IC90) IC50 Dynamic range (IC80-IC20) Slope 
PBS 0.5 ng/mL (0.85 nM) 43.2 ng/mL (73.8 nM) 2.3– 809 ng/mL (3.9-1383 nM) -0.41 
PBST 0.1 ng/mL (0.17 nM) 1.3 ng/mL (2.3 nM) 0.3 – 5.4 ng/mL (0.51-9.2 nM) -1.02 
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